126501-70-0

Usage

Uses

Used in Pharmaceutical Industry:
1-(2,2,2-TRIFLUOROACETYL)-4-PIPERIDINECARBOXYLIC ACID is used as a key intermediate in the synthesis of various pharmaceuticals for its ability to enhance the stability and reactivity of the compounds being developed. Its trifluoroacetyl group contributes to the modification of drug properties, potentially improving their efficacy, selectivity, and pharmacokinetics.
Used in Agrochemical Development:
In the agrochemical sector, 1-(2,2,2-TRIFLUOROACETYL)-4-PIPERIDINECARBOXYLIC ACID is utilized as an intermediate in the creation of compounds designed to protect crops and enhance agricultural productivity. Its chemical properties allow for the development of novel agrochemicals with improved performance and selectivity towards target pests or diseases.
Used in Organic Synthesis:
1-(2,2,2-TRIFLUOROACETYL)-4-PIPERIDINECARBOXYLIC ACID is employed as a versatile building block in organic synthesis, where its trifluoroacetyl group can be selectively manipulated to form a range of complex organic molecules. This makes it suitable for the preparation of specialty chemicals, advanced materials, and other精细化化学品.
Each application leverages the unique attributes of 1-(2,2,2-TRIFLUOROACETYL)-4-PIPERIDINECARBOXYLIC ACID, such as its stability and reactivity, to fulfill specific needs across different industries.

InChI:InChI=1/C8H10F3NO3/c9-8(10,11)7(15)12-3-1-5(2-4-12)6(13)14/h5H,1-4H2,(H,13,14)

Upstream product

• 498-94-2 isonipecotic acid 
• 407-25-0 trifluoroacetic anhydride 
• 358-23-6 trifluoromethylsulfonic anhydride 

Downstream Products

• 120848-76-2 (3,4-dihydroisoquinolin-2(1H)-yl) (piperidin-4-yl)methanone 
• 138007-24-6 4-tert-butyl piperidine-4-carboxylate 
• 276236-96-5 4-(3-phenyl-[1,2,4]oxadiazol-5-yl)-piperidine 
• 73415-85-7 N-phenyl-4-piperidinecarboxamide 
• 73415-60-8 (3,4-dihydro-1H-isoquinolin-2-yl)-piperidin-4-yl-methanone; hydrochloride 
• 1025813-61-9 (2,6-dimethyl-phenyl)-[4'-methyl-4-(4-methylsulfanyl-benzoyl)-[1,4']bipiperidinyl-1'-yl]-methanone 

Relevant academic research and scientific papers

Conformation-activity relationship study of 5-HT3 receptor antagonists and a definition of a model for this receptor site

A conformation-activity relationship study of 5-HT3 receptor antagonists was used to define a pharmacophore and receptor map to qualitatively account for their activity. The design and synthesis of specific keto-amino-indole derivatives that are potent 5-HT3 receptor antagonists gave some support to the model.

1-Aminopyridinium Ylides as Monodentate Directing Groups for sp3 C-H Bond Functionalization

1-Aminopyridinium ylides are efficient directing groups for palladium-catalyzed β-arylation and alkylation of sp3 C-H bonds in carboxylic acid derivatives. The efficiency of these directing groups depends on the substitution at the pyridine moiety. The unsubstituted pyridine-derived ylides allow functionalization of primary C-H bonds, while methylene groups are unreactive in the absence of external ligands. 4-Pyrrolidinopyridine-containing ylides are capable of C-H functionalization in acyclic methylene groups in the absence of external ligands, thus rivaling the efficiency of the aminoquinoline directing group. Preliminary mechanistic studies have been performed. A cyclopalladated intermediate has been isolated and characterized by X-ray crystallography, and its reactivity was studied.

CHEMOKING RECEPTOR ANTAGONISTS

Disclosed herein are chemokine receptor antagonists of formula (I) wherein G1, X1, X2, and X3 are as defined in the specification. Compositions comprising such compounds; and methods for treating conditions and disorders using such compounds and compositions are also described.

PIPERIDINE DERIVATIVES USEFUL AS CCR5 ANTAGONISTS

Pharmaceutical compositions for the treatment of HIV are provided comprising compounds of formula (II) or a pharmaceutically acceptable salt or isomer thereof, in combination with specified antiviral agents.

Xanthamide fluorescent dyes

Two derivatives of fluorescein, termed "xanthamides," were prepared from fluorescein, an inexpensive dye. Relative to fluorescein, which contains a 6-phenolic OH and a 2′-carboxyl, the first derivative (5) contains a carboxymethyl ether at the 6-position

Synthesis, SAR, and biological evaluation of oximino-piperidino-piperidine amides. 1. Orally bioavailable CCR5 receptor antagonists with potent anti-HIV activity

We previously reported the discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl-3 -pyridinyl)carbonyl]-4′-methyl-1,4′-bipipefidine N-oxide 1 (SCH 351125) as an orally bioavailable human CCR5 antagonist for the treatment of HIV-1 infec

Discovery of 4-[(Z)-(4-bromophenyl)(ethoxyimino)methyl]-1′-[(2,4-dimethyl- 3pyridinyl)carbonyl]-4′-methyl-1,4′bipiperidine N-oxide (SCH 351125): An orally bioavailable human CCR5 antagonist for the treatment of HIV infection

Structure - activity studies on piperidino-piperidine 3 led to the discovery of SCH 351125 (1), a selective CCR5 antagonist with potent activity against RANTES binding (Ki=2 nM), which possesses subnanomolar activity in blocking viral entry and

Antagonism of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane stimulus with a newly identified 5-HT2- versus 5-HT(1C)-selective antagonist

DOM [i.e., 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane] is a 5- HT(1C/2) serotonin agonist that exerts stimulus control of behavior in animals. In order to determine if the discriminative stimulus effect of DOM is 5-HT(1C)- or 5-HT2-mediated, it would be informative to conduct tests of stimulus antagonism with a 5-HT(1C)- or 5-HT2-selective antagonist. To date, no such agents exist. Although the neuroleptic agent spiperone binds at D2 dopamine receptors and 5-HT(1A) serotonin receptors, (a) it displays about a 1000-fold selectivity for 5-HT2 versus 5-HT(1C) sites and (b) it has been used as a '5-HT2-selective' antagonist. Because spiperone is a behaviorally disruptive agent, it is not suitable for use in drug-discrimination studies. Using the spiperone molecule as a starting point, a limited structure- affinity investigation was conducted in order to identify a suitable antagonist with high affinity and selectivity for 5-HT2 receptors, and yet an antagonist that might lack the disruptive actions of spiperone. Various modifications of the spiperone molecule were examined, but most resulted in decreased 5-HT2 affinity or in loss of selectivity. One compound, 8-[3-(4- fluorophenoxy)propyl]-1-phenyl-1,3,8-triazaspiro[4.5]decan-4-one (26), was shown to bind at 5-HT2 sites with high affinity (K(i) = 2 nM) and >2,000- fold selectivity versus 5-HT(1C) sites. In tests of stimulus antagonism using rats trained to discriminate 1 mg/kg of DOM from saline vehicle, 26 behaved as a potent antagonist (ED50 = 0.003 mg/kg) and lacked the disruptive effects associated with spiperone. As such, (a) it would appear that the DOM stimulus is primarily a 5-HT2-mediated, and not 5-HT(1C)-mediated, phenomenon, and (b) compound 26 may find application in other pharmacologic investigations where spiperone may not be a suitable antagonist.